Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
出版年份 2015 全文链接
标题
Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
作者
关键词
-
出版物
OncoImmunology
Volume 5, Issue 7, Pages e1052212
出版商
Informa UK Limited
发表日期
2015-08-17
DOI
10.1080/2162402x.2015.1052212
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
- (2015) Siwen Hu-Lieskovan et al. Science Translational Medicine
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Combining Targeted Therapy With Immunotherapy inBRAF-Mutant Melanoma: Promise and Challenges
- (2014) Siwen Hu-Lieskovan et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
- (2014) T. Bald et al. Cancer Discovery
- Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
- (2014) Z. A. Cooper et al. Cancer Immunology Research
- BRAF-targeted therapy alters the functions of intratumoral CD4+T cells to inhibit melanoma progression
- (2014) Ping-Chih Ho et al. OncoImmunology
- Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination
- (2013) I. Melero et al. CLINICAL CANCER RESEARCH
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
- (2013) Deborah A. Knight et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression
- (2013) Georgina V. Long et al. Pigment Cell & Melanoma Research
- Vemurafenib enhances MHC induction inBRAFV600Ehomozygous melanoma cells
- (2013) Bishu Sapkota et al. OncoImmunology
- Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
- (2013) Zachary A. Cooper et al. OncoImmunology
- Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies
- (2012) I. Verbrugge et al. CANCER RESEARCH
- BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy
- (2012) Richard C. Koya et al. CANCER RESEARCH
- BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
- (2012) C. Liu et al. CLINICAL CANCER RESEARCH
- The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
- (2012) X. Jiang et al. CLINICAL CANCER RESEARCH
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dual Anti-OX40/IL-2 Therapy Augments Tumor Immunotherapy via IL-2R-Mediated Regulation of OX40 Expression
- (2012) William L. Redmond et al. PLoS One
- The HIF-1α Hypoxia Response in Tumor-Infiltrating T Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy
- (2012) Asís Palazón et al. Cancer Discovery
- Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma
- (2012) Anna Hooijkaas et al. OncoImmunology
- BRAF inhibition improves tumor recognition by the immune system
- (2012) Marco Donia et al. OncoImmunology
- Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey
- (2011) B. B. Aggarwal et al. BLOOD
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
- (2011) James S. Wilmott et al. CLINICAL CANCER RESEARCH
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Control of Immunity by the TNFR-Related Molecule OX40 (CD134)
- (2010) Michael Croft Annual Review of Immunology
- Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
- (2010) A. Boni et al. CANCER RESEARCH
- Myeloid-derived suppressor cell heterogeneity and subset definition
- (2010) Elisa Peranzoni et al. CURRENT OPINION IN IMMUNOLOGY
- Combination Therapy of Established Tumors by Antibodies Targeting Immune Activating and Suppressing Molecules
- (2010) K. Takeda et al. JOURNAL OF IMMUNOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity
- (2008) K. Movahedi et al. BLOOD
- Combination Therapy with Cisplatin and Anti-4-1BB: Synergistic Anticancer Effects and Amelioration of Cisplatin-Induced Nephrotoxicity
- (2008) Y. H. Kim et al. CANCER RESEARCH
- Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells
- (2008) Ilaria Marigo et al. IMMUNOLOGICAL REVIEWS
- Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice
- (2008) Seong-A Ju et al. INTERNATIONAL JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started